CA1341262C - A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine - Google Patents
A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine Download PDFInfo
- Publication number
- CA1341262C CA1341262C CA000543832A CA543832A CA1341262C CA 1341262 C CA1341262 C CA 1341262C CA 000543832 A CA000543832 A CA 000543832A CA 543832 A CA543832 A CA 543832A CA 1341262 C CA1341262 C CA 1341262C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- alkyl
- process according
- enamine
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 title claims abstract description 41
- 229960003048 vinblastine Drugs 0.000 title claims abstract description 32
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 title claims abstract description 31
- 230000008569 process Effects 0.000 title claims abstract description 28
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 title claims abstract description 8
- 229960004528 vincristine Drugs 0.000 title claims abstract description 8
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 title claims abstract description 8
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 title claims 2
- 230000015572 biosynthetic process Effects 0.000 title description 23
- 238000003786 synthesis reaction Methods 0.000 title description 14
- 150000002081 enamines Chemical class 0.000 claims abstract description 71
- 239000000543 intermediate Substances 0.000 claims abstract description 56
- -1 alkaloid compounds Chemical class 0.000 claims abstract description 19
- 230000001590 oxidative effect Effects 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 claims abstract description 9
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 claims abstract description 9
- 230000009466 transformation Effects 0.000 claims abstract description 9
- 229930013930 alkaloid Natural products 0.000 claims abstract description 7
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000539 dimer Substances 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 14
- GKWYINOZGDHWRA-UHFFFAOYSA-N catharanthine Natural products C1C(CC)(O)CC(CC2C(=O)OC)CN1CCC1=C2NC2=CC=CC=C12 GKWYINOZGDHWRA-UHFFFAOYSA-N 0.000 claims description 14
- 239000003638 chemical reducing agent Substances 0.000 claims description 14
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- WVTGEXAIVZDLCR-UHFFFAOYSA-N Vindoline Natural products CC1C2CN3CCCC14CCC5Nc6ccccc6C25C34 WVTGEXAIVZDLCR-UHFFFAOYSA-N 0.000 claims description 7
- 238000005273 aeration Methods 0.000 claims description 7
- CMKFQVZJOWHHDV-DYHNYNMBSA-N catharanthine Chemical compound C([C@@H]1C=C([C@@H]2[C@@]3(C1)C(=O)OC)CC)N2CCC1=C3NC2=CC=CC=C12 CMKFQVZJOWHHDV-DYHNYNMBSA-N 0.000 claims description 7
- CXBGOBGJHGGWIE-IYJDUVQVSA-N vindoline Chemical compound CN([C@H]1[C@](O)([C@@H]2OC(C)=O)C(=O)OC)C3=CC(OC)=CC=C3[C@]11CCN3CC=C[C@]2(CC)[C@@H]13 CXBGOBGJHGGWIE-IYJDUVQVSA-N 0.000 claims description 7
- 150000004075 acetic anhydrides Chemical class 0.000 claims description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 6
- 239000012346 acetyl chloride Substances 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- AGNTUUNJYRDJCW-UHFFFAOYSA-N 1-[(1-benzyl-4H-pyridin-3-yl)methylamino]pyrrolidine-2-carboxamide Chemical compound C1CC(N(C1)NCC2=CN(C=CC2)CC3=CC=CC=C3)C(=O)N AGNTUUNJYRDJCW-UHFFFAOYSA-N 0.000 claims description 3
- WJNYVKCAEHASOF-UHFFFAOYSA-N 1-benzyl-4h-pyridine-3-carbonitrile Chemical compound C1=CCC(C#N)=CN1CC1=CC=CC=C1 WJNYVKCAEHASOF-UHFFFAOYSA-N 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- JIJVOHRWYUICGU-UHFFFAOYSA-N 1-benzhydryl-4h-pyridine-3-carboxamide Chemical compound C1=CCC(C(=O)N)=CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 JIJVOHRWYUICGU-UHFFFAOYSA-N 0.000 claims description 2
- RFURHRKBOOHVBM-UHFFFAOYSA-N dimethyl 2-(3-carbamoyl-4h-pyridin-1-yl)butanedioate Chemical compound COC(=O)CC(C(=O)OC)N1C=CCC(C(N)=O)=C1 RFURHRKBOOHVBM-UHFFFAOYSA-N 0.000 claims description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 28
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 150000003797 alkaloid derivatives Chemical group 0.000 abstract description 4
- 238000005580 one pot reaction Methods 0.000 abstract description 4
- 241000208328 Catharanthus Species 0.000 abstract description 2
- 241000863480 Vinca Species 0.000 abstract description 2
- 230000000719 anti-leukaemic effect Effects 0.000 abstract description 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 238000006722 reduction reaction Methods 0.000 description 44
- 239000000243 solution Substances 0.000 description 31
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 26
- 239000000047 product Substances 0.000 description 23
- 238000004007 reversed phase HPLC Methods 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KGUMNRYFUFLBGA-UHFFFAOYSA-N 1,4-dihydropyridine-3-carboxamide Chemical class NC(=O)C1=CNC=CC1 KGUMNRYFUFLBGA-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- LEDCFITVWDCVCB-UHFFFAOYSA-N methyl 2-(3-carbamoyl-4h-pyridin-1-yl)-3-methylbutanoate Chemical compound COC(=O)C(C(C)C)N1C=CCC(C(N)=O)=C1 LEDCFITVWDCVCB-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical compound C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 241001661930 Aspidosperma Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001246918 Tabernanthe iboga Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present application relates to a method for producing dimer alkaloid compounds especially of the Catharanthus (Vinca) alkaloid groups and, in particular, for producing the anti-viral, anti-leukemic (antineoplastic) compounds vincristine and vinblastine. Use of selected 1,4-dihydropyridine compounds for the 1,4-reduction of an iminium intermediate to an enamine results in significant increase in the yield of the enamine.
Parameters for the oxidative transformation of enamine to the iminium intermediates and subsequent reduction of the iminium intermediates to vinblastine and leurosidine are disclosed. The overall process, conducted in a one-pot operation, producing vinblastine, leurosidine and 3',4'-dehydrovinblastine is described.
Parameters for the oxidative transformation of enamine to the iminium intermediates and subsequent reduction of the iminium intermediates to vinblastine and leurosidine are disclosed. The overall process, conducted in a one-pot operation, producing vinblastine, leurosidine and 3',4'-dehydrovinblastine is described.
Description
Process for the Synthesis of Vinblastine and Vincristine Field of the Invention The present application relates to a further improvement of a new and improved method for producing dimer alkaloid compounds especially of the Catharanthus (Vinca) alkaloid groups and, in particular, is a further improved method for producing the anti-viral, anti-leukemic (antineoplastic) compounds, vincristine and vinblastine of Formula I.
Iorrr.~rr>
o~~ v.~
frr~r.c) I
The above compound, when R is COOCH3, and Rl is OCH3, is vinblastine (NSC 49482) and when R is COOCH3, and Rl is OCH3 and N1 is N-CHO (N-formyl), vincristine (NSC
67574).
The present series of dimeric alkaloids, including important antitumor agents, are formed from an indole, such as catharanthine (Formula II, R - COOCH3), and a dihydroindole unit, e.g., vindoline (Formula III:), in which ~ 3 4 ~-z s z ._ the halves are linked via a carbon-carbon bond involving an aliphatic center Cl~ in the indole unit and an aromatic carbon C15 in the vindoline portion.
h a C00C 1i II III
Summarv of the Invention The specific improvements in the present applica-tion are set out below.
Firstly, improvement of the novel reduction method, in which conversion of the iminium intermediate (Formula VI) to the enamine (Formula VIII) '~34i2fiZ
_,....
~N_~
~ ~nR = H..., ~.'-' V ~doline ;' ON
Cti3 D ~ " ~t~'~'~'' O~ -CH3 C~i3 R p vi R=CC Ct~!
~o?N a i O I ~ ~ _ .,., _~ _..,-r.' '~'~
I
O
CH30 ~' ~'' Oi -Cti3 CH3 R p VI I I R=C02 CH3 ~~34~2s2 as described in step (e), post, is achieved by the use of various new 1,4-dihydronicotinamides (Formula IX, R2 - R4 -R5 - R6 - H; R3 - CONH2 and R1 may contain different functional groups ;such as aryl, caqrboxylic esters, sugars, carboxylic acid, and carboxylate salt, as represented by Formulae XXVII to XXXII listed in Table 1) and 1,4-dihydropyridine compounds such as Formulae XXXIII and XXXIV.
Of special importance is the presence of electron rich functional groups (e. g., carboxylic esters and carboxylate salts in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction ) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII). Further improvement in the formation of the latter compound is achieved by performing the reduction of iminium intermediate (Formula VI) and maintaining the reaction mixture before any subsequent manipulation at a low temperature (0 to -70°C) preferably below -40°C.
p Rs R3 Re R
z R, IX
'1341262 Specific examples related to the above improve-ments for the synthesis of enamine (Formula VIII) by the 1,4-reduction of the iminium intermediate (Formula VI) are given in the Examples 1-9 (Procedures C to K) . Results of these examples are summarized in Tables 2 and 3. Table 2 indicates reduction procedures (Procedures I and J as in Examples 7 and 8), employing reducing agents Formula XXXI
and Formula XXXII, respectively, afford the best yields of the enamine (Formula VIII). Table 3 shows the effect of temperature in the reduction of iminium intermediate (Formula VI) by the reducing agent Formula XXXII. Lowering the reduction temperature to -40°C (Procedure K(ii) Example 9) resulted in an increase in both the ratio of 1,4-reduction production, enamine (VIII), versus 1,2-reduction product, 3,4-dehydrovinblastine (VII), (4.2:1), as well as the overall yield of the reaction (85~).
The second area of improvement relates to the oxidative transformation of the enamine (Formula VIII) to the iminium intermediate (Formula XVI).
Various parameters for this oxidative transformation have been studied to optimize the yield of vinblastine (Formula I) production.
Table 4 indicates the effect of ferric chloride concentration. Two equivalents of ferric chloride provide the highest yield of vinblastine (I).
13~12f~2 ' _ 'r: E
z - o >
. ~ c w .r G
~rl w an N
v a G ..
r1 .,.1 N ~
r .., .b w I
o .J
G
O M
-.1 v 1~
U
'O
J
U
~ U~~ M
, O
, '_" U
, I Z ~ U
.- . ~
w ~ 'z~' V ' ~' ~ LL
Z1,~~ ~
.
' _ .
O
U
:c v r w a a~ A w 0.
N
~~ I
O a p ~ C~
Z
- ~ .n ~ .n v V U V V
p v _ H _ Z- U Z~
a ~4 a ~4 L1 fir V jp '" ~,i >w.
a.
'~ ,,~ ,~ : O : v U ~o v N ~ n ~ ~ < Z
Z O = t,~ c~, .p O c~ ~c N ~r p _ Z- ~ ~ ~ ~ o 0 v ...~,. ..,~.. 0G ~ ?e b II V v II r r r a N
r1 r~
H h~l N
w Table 2. Effect of Reducing Agent on I,~- vs. 1,2-keduction of Iminiuu ~'i Reduction Procedurel'4 1,4:1,2-Reduction Pzoducts' Yield3 (~) E~ 1:1 75 1:1 60 0.9:1.0 60 v 1:1 40 1.1:1 60 2:1 65 1.5:1 70 1.1:1 65 I 2.3:1 70 J 2.2:1 70 1 Typical Procedure: 100 mg Iminiua VI in 6 ml methanol to which reducing aitenta C-J (1-6 eq.) distolved in 6 ml :ethanol weze added. F~11 details in Fxpeziaental Section.
2 B~ reverse phase HPLC quantitation.
Combined 1,2-reduction (3,4-dehydrovinblastine, VII) + 1,4-reduction tenamiae VIII) products.
4 All of these reactions were co~ucted at 20° C.
Procedures A and B are resented in Canadian p application Serial No.
57,897 and presented here for oar~parison.
~3~fizsz Table 3. Effect of Temperature on 1,4- vs. 1,2-Reduction of Iminiug VI.
Reduction Procedural Teap. (°C) 1,4:1,2-Reduction Products2 Yield3 (t) D 20 2.2:1 70 K (i) -20 3.2:1 80 X (ii) -40 4.2:1 85 1 Typical procedure as in Table 2.
Quantiution by IiPLC.
Cosbined 1,2-reduction (3,4-dehydrovinblastixe, VII) ~ 1,4-reduction (examine VIII) products.
Table ~. Effect of Ferric C~t~loride on Production of Vinblastine (I) f rou Ena~ine VIII3 Amount of FeCi; Orxidation Conditions ! Yield of (Equivalentsl'' (Temp., time) Vinblastine2 p Aizi, Oo C, 5 min 0 I Air , 0 C, 5 min 13.3 l Air C, S min 19.0 , 0 3 Airl, 0 C, 5 min 10.4 pt a rate of 6U ml/min.
B~ revezee-phase HPLC quantiution, after reductive work-up with NaBH4.
3 Ensmine VIII itenerated at -4D° C (Procedure K (ii)).
1341'262 Table 5. Effect of Time of Oxidation on Production of Vinblastine (I) froa Enamine VIII3 Timel (min) a Yield of 2 Vinblastine 1 8.2 15.4 15.5 15.7 45 6.5 Reaction conditions: - 2 eq. ferric chlorine added, air bubbled throu,~ the solution at 60 ~1/min at 0° C.
2 By reverse-phase BpI~C quaatitation aftxr reductive work-up s~ith NaBIi4.
~namine DIII generated at -40° C (Procedure K (ii)).
13412fi2 ~abie E. Effect of Oxidation TemperaturE on Production of t~inbiastine (I) f roa Ena~ine VIII3 TemF., ° CI ~ Yield of 2 vinblastine -40 3..
-23 6.?
0 19.6 20 20.6 16.0 Reaction conditions: 2 eq. ferric chloride added, air bubbled through the solution at 60 sl/~in for 15 mir..
By reverse-phase HPLC quantitation after reductive work-up with NaBP.4.
Enamine generated at -40° C (Procedure K (fi)).
Table 7. Effect of Dilution on Production of Vinblastine (I) frog Enamine vIIT3 Dilution Factorl'4 1 Yield of 2 Vinblastine 1 19.6 25.2 30.1 29.6 50 24.7 1 iteactian conditions: 2 eq. ferric chloride added, air bubbled through the solution at 60 slain for 15 :in. at 0° C.
2 By reverse-phase xPI~C quantitation after reductive work-up with NaBIi4.
Enamine Generated at -40° C (Procedure R (ii)).
~' Dilution Factor 1 ~ 100 ~g Isinium 'VI in 6 :1 sethanol to ~rhich reducing agent Formula III (6 aq.) in 6 st2 ~ethaaol vas added.
(Total voluae ~ 1~ ~1) Dilution Factor 5 ~ Total voltme of b0 ml, etc.
13412fi2 Table 5 indicates results relating to yield of vinblastine versus time of oxidation. The maximum yield of vinblastine (I) is reached after 5 to 20 minutes of aeration in the presence of 2 equivalents of ferric chloride.
Table 6 shows the results of various oxidation temperatures, in the presence of two equivalents of ferric chloride, on the yield of vinblastine (I). The temperature range of 0°C to 20°C provides the highest yield of vinblastine (I) after a reductive work-up with NaBH4, as quantified by reverse-phase HPLC.
The effect of dilution of the enamine (VIII) solution on the production of vinblastine (I), is indicated in Table 7. A dilution factor of 10 to 20 on the enamine (VIII) solution before aeration in the presence of ferric chloride (2 equivalents) at 0°C, affords the best yield of vinblastine (I) as quantified by reverse-phase HPLC after reductive work-up with NaBH4.
In summary, the specific improvements in the present application as they relate to the oxidative trans-formation of the enamine (VIII), involve the dilution (5 to 50 folds) of the enamine (Formula VIII) solution, obtained in the above reduction of iminium intermediate (Formula VI), by the same solvent used in the reduction. For practical purposes, the preferred dilution factor is usually in the range of 8 to 12 folds. The above procedure is conducted at a low temperature (0°C to -70°C), preferably below -40°C and under cover with inert conditions such as argon or an inert gas of Group Zero of the Periodic Table (nitrogen, helium, neon, etc.). After this dilution process, the oxidative transformation of the enamine (Formula VIII) can be carried out as described above (aeration at 60 ml/min for 15 min at 0°C in the presence of ferric chloride (2 eq.)) to afford the corresponding iminium intermediates (Formula XVI).
OOf l N...
- _H_ -~.- t7-r H ,.:
_~ I
vindof ine O OH
CH30 ~ ~O~ "CH3 Formula RVI
The third area of improvement relates to the reduction of iminium intermediates (Formula XVI) by alkali metal borohydride (NaBH4, KBH4, LibH4, etc.) to vinblastine (Formula I) and/or leurosidine (Formula XXXV). The iminium intermediates (Formula XVI and Formula XVIa) produced from the oxidative transformation of enamine (Formula VIII) are reduced by the addition of alkali metal borohydride at low temperature (4°C to -20°C), preferably at 0°C. The reduc-tion is conducted at pH lower than 8.5 and preferably at 7.5 to 8. The total reaction mixture is then concentrated in vacuo at low temperature (0°C to 10°C) before extraction and isolation of alkaloid products.
1 347 2fi 2 H
I R N ~ ~ ~t oo~
O RN-H'w~--~ I 1 _H_.-w ~"'~
I
off CH30 N~O~ -CH3 O OH
CH3 R 0 CH3 0 ~~ Oy'CH3 R=COy~i3 CH3~ 0 R=C0yCH3 Formula XXXV (Leurosidine) Formula XVIa For practical purposes, all the above improvements can be incorporated, as indicated, directly into the overall process conducted in a one-pot operation from the indole unit (Formulas II, XXII or XXIII) and the dihydroindole unit (Formula XXI, R - H) to the final products of Formula XXI.
Isolation of the various intermediates (Formulas XXIV, VI, VIII and XVI) is omitted as summarized in Scheme 1.
In summary, the present method is applicable to the production of dimer products from catharanthine and dihydrocatharanthine with vindoline as starting materials and phenyl, alkyl and amide derivatives embraced by the following formulas:
Scneme 1. Optimum procedure for one-pot process - vinblastine from catharanthine and vindoline.
D
r ca~c~
XXtV
~C~3CO~Z O l 1 _60 o C !i 0 t OH ~ _Cti~
C, yr OKs o (r CONIiZ
l t 3 c t.Z-Reduction f Enamine Anhydrovinbls~tme R~tso t.Z:1 1 34i 262 Scneu~_ : - cor,:inue~
h' ..
J
CH~O ~''~''~'!~~-Ct~
R ~ Gp2Ct~3 vllt FeCI 2 a uiv.), 0° C
Air. ~~ mi9min. !5 min Dilution Factor 10 00 ff ~ ooH
CiisO ~~ ~~~_C~~
XVI
XVIe NvBii~ N~Bfix _C+~i X341262_ Formula XXI is as pictured and in that formula alk represents a lower alkyl group of Cl-C6 and preferably Cl-C3; aryl is mono-aryl such as benyzl, styryl, and xylyl; Rl is a member of the group consisting of hydrogen, alk, CHO
and COR5 where R5 is alkyl or aryl; R2 and R3 are members of the group consisting of hydrogen and -CO-alk; R4 is a member of the group consisting of COO-alk, CONH-NH2, CONH2, CONHR6, and CON(R6)2 where R6 is alkyl; Z is a member of the group consisting of -CH2-CH2- and -CH-CH- and R is a member of the indole family represented by Formula XXII
where R~ is a member of the group consisting of hydrogen, or COO-alk; R8 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk or alkyl; R9 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk, or alk; R10 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk, or Formula XXIII where R11 is a member of the group consisting of hydrogen or COO-alk; R12 is a member consisting of alkyl.
SEecific Description of the Invention This invention is specifically a process for the production of compounds represented by the following formulas:
s XXI
n s' o-~z iO n ~ i 1W' 13412fi2 xIi x XXIII
G
wherein in Formula XXI
Alkyl = CH3 or (CH2)nXH3 where n=1-5 Rl - CH3 or CHO
R2 - H or CO-alk R4 - COO-alk or CONR13R14 where R13 and R14 can be any member of the group consisting of hydrogen, alkyl, substituted alkyl, aryl or substituted aryl functions Z - -CH=CH- or -CH2-CH2-R - Formula XXII or XXIII
R~ - or COO-alk H
R8 - OH, O-alk, OCO-alk or alkyl H, R~ - OH, O-alk, OCO-alk or alkyl H, R1~ - OH, O-alk, OCO-alk H, R11 - or COO-alk H
R12 - or alkyl H
wherein the process a dimer derived is for the synthesis of from an indole unit of the natural Iboga alkaloid family containing an a dihydroindole aza bicyclo-octane portion and 13~~~62 unit of the natural Aspidosperma and Vinca alkaloid families, the stereochemistry of the carbon-carbon linkage between these two units being identical with that of vinblastine which consists of (a) forming an N-oxide intermediate in the cold at a temperature of -70°C to +40°C from said indole unit by oxidizing the bridge nitrogen and without isolating said intermediate;
(b) treating said 2~-oxide indole intermediate in the presence of one member of the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride to effect a Polonovski-type fragmentation reaction;
(c) without isolating the product of step (b), coupling said reaction product with a dihydroindole unit in the presence of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to +40°C under inert conditions;
(d) the product of step (c) is solated by solvent evaporation preferably at low temperature in the range of -20°C to 0°C;
(e) the product of step (d) is reduced by 1,4-dihydropyridine compounds represented by Formula IX
H Rw R R, IX
~Z
Ri where R3 and R5 in Formula IX are carboxylic esters (COO-alk) and Rl, R2, R4 and R6 are members of the group consisting of H, alkyl, aryl (Hantzch ester series) or tv-substituted 1,4-dihydronicotinamides where R1 is a substituted alkyl or substituted aryl function, for example, benzyl, and R3 is CONR~RB where R~ and R8 is one member of the group consisting of hydrogen, alkyl or aryl function;
(f) the product of step (e), an enamine, Formula VIII, is isolated by solvent evaporation, preferably at low temperature in the range of -20°C to 0°C;
(g) the product of step (e), a solution of enamine VIII, is diluted (5 to 50 folds) by the same solvent employed, preferably in the range of 8 to 12 folds at a low temperature (0°C to -70°C), preferably below -40°C;
(h) the enamine obtained in step (f) or the enamine solution obtained in step (g) is used to prepare iminium intermediates, Formula XVI or XVIa, by a number of oxidative processes including:
(1) controlled aeration/oxygenation in which a solution of the enamine is stirred in open air or with a stream of air/oxygen bubbled through the solution;
(2) as in (1) but with the addition of a metal ion;
(3) as in (1) but with the addition of a flavin coenzyme, as represented by Formula XII, to generate, in situ, the corresponding 1,5-dihydroflavin coenzyme, as represented by Formula XIII;
Iorrr.~rr>
o~~ v.~
frr~r.c) I
The above compound, when R is COOCH3, and Rl is OCH3, is vinblastine (NSC 49482) and when R is COOCH3, and Rl is OCH3 and N1 is N-CHO (N-formyl), vincristine (NSC
67574).
The present series of dimeric alkaloids, including important antitumor agents, are formed from an indole, such as catharanthine (Formula II, R - COOCH3), and a dihydroindole unit, e.g., vindoline (Formula III:), in which ~ 3 4 ~-z s z ._ the halves are linked via a carbon-carbon bond involving an aliphatic center Cl~ in the indole unit and an aromatic carbon C15 in the vindoline portion.
h a C00C 1i II III
Summarv of the Invention The specific improvements in the present applica-tion are set out below.
Firstly, improvement of the novel reduction method, in which conversion of the iminium intermediate (Formula VI) to the enamine (Formula VIII) '~34i2fiZ
_,....
~N_~
~ ~nR = H..., ~.'-' V ~doline ;' ON
Cti3 D ~ " ~t~'~'~'' O~ -CH3 C~i3 R p vi R=CC Ct~!
~o?N a i O I ~ ~ _ .,., _~ _..,-r.' '~'~
I
O
CH30 ~' ~'' Oi -Cti3 CH3 R p VI I I R=C02 CH3 ~~34~2s2 as described in step (e), post, is achieved by the use of various new 1,4-dihydronicotinamides (Formula IX, R2 - R4 -R5 - R6 - H; R3 - CONH2 and R1 may contain different functional groups ;such as aryl, caqrboxylic esters, sugars, carboxylic acid, and carboxylate salt, as represented by Formulae XXVII to XXXII listed in Table 1) and 1,4-dihydropyridine compounds such as Formulae XXXIII and XXXIV.
Of special importance is the presence of electron rich functional groups (e. g., carboxylic esters and carboxylate salts in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction ) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII). Further improvement in the formation of the latter compound is achieved by performing the reduction of iminium intermediate (Formula VI) and maintaining the reaction mixture before any subsequent manipulation at a low temperature (0 to -70°C) preferably below -40°C.
p Rs R3 Re R
z R, IX
'1341262 Specific examples related to the above improve-ments for the synthesis of enamine (Formula VIII) by the 1,4-reduction of the iminium intermediate (Formula VI) are given in the Examples 1-9 (Procedures C to K) . Results of these examples are summarized in Tables 2 and 3. Table 2 indicates reduction procedures (Procedures I and J as in Examples 7 and 8), employing reducing agents Formula XXXI
and Formula XXXII, respectively, afford the best yields of the enamine (Formula VIII). Table 3 shows the effect of temperature in the reduction of iminium intermediate (Formula VI) by the reducing agent Formula XXXII. Lowering the reduction temperature to -40°C (Procedure K(ii) Example 9) resulted in an increase in both the ratio of 1,4-reduction production, enamine (VIII), versus 1,2-reduction product, 3,4-dehydrovinblastine (VII), (4.2:1), as well as the overall yield of the reaction (85~).
The second area of improvement relates to the oxidative transformation of the enamine (Formula VIII) to the iminium intermediate (Formula XVI).
Various parameters for this oxidative transformation have been studied to optimize the yield of vinblastine (Formula I) production.
Table 4 indicates the effect of ferric chloride concentration. Two equivalents of ferric chloride provide the highest yield of vinblastine (I).
13~12f~2 ' _ 'r: E
z - o >
. ~ c w .r G
~rl w an N
v a G ..
r1 .,.1 N ~
r .., .b w I
o .J
G
O M
-.1 v 1~
U
'O
J
U
~ U~~ M
, O
, '_" U
, I Z ~ U
.- . ~
w ~ 'z~' V ' ~' ~ LL
Z1,~~ ~
.
' _ .
O
U
:c v r w a a~ A w 0.
N
~~ I
O a p ~ C~
Z
- ~ .n ~ .n v V U V V
p v _ H _ Z- U Z~
a ~4 a ~4 L1 fir V jp '" ~,i >w.
a.
'~ ,,~ ,~ : O : v U ~o v N ~ n ~ ~ < Z
Z O = t,~ c~, .p O c~ ~c N ~r p _ Z- ~ ~ ~ ~ o 0 v ...~,. ..,~.. 0G ~ ?e b II V v II r r r a N
r1 r~
H h~l N
w Table 2. Effect of Reducing Agent on I,~- vs. 1,2-keduction of Iminiuu ~'i Reduction Procedurel'4 1,4:1,2-Reduction Pzoducts' Yield3 (~) E~ 1:1 75 1:1 60 0.9:1.0 60 v 1:1 40 1.1:1 60 2:1 65 1.5:1 70 1.1:1 65 I 2.3:1 70 J 2.2:1 70 1 Typical Procedure: 100 mg Iminiua VI in 6 ml methanol to which reducing aitenta C-J (1-6 eq.) distolved in 6 ml :ethanol weze added. F~11 details in Fxpeziaental Section.
2 B~ reverse phase HPLC quantitation.
Combined 1,2-reduction (3,4-dehydrovinblastine, VII) + 1,4-reduction tenamiae VIII) products.
4 All of these reactions were co~ucted at 20° C.
Procedures A and B are resented in Canadian p application Serial No.
57,897 and presented here for oar~parison.
~3~fizsz Table 3. Effect of Temperature on 1,4- vs. 1,2-Reduction of Iminiug VI.
Reduction Procedural Teap. (°C) 1,4:1,2-Reduction Products2 Yield3 (t) D 20 2.2:1 70 K (i) -20 3.2:1 80 X (ii) -40 4.2:1 85 1 Typical procedure as in Table 2.
Quantiution by IiPLC.
Cosbined 1,2-reduction (3,4-dehydrovinblastixe, VII) ~ 1,4-reduction (examine VIII) products.
Table ~. Effect of Ferric C~t~loride on Production of Vinblastine (I) f rou Ena~ine VIII3 Amount of FeCi; Orxidation Conditions ! Yield of (Equivalentsl'' (Temp., time) Vinblastine2 p Aizi, Oo C, 5 min 0 I Air , 0 C, 5 min 13.3 l Air C, S min 19.0 , 0 3 Airl, 0 C, 5 min 10.4 pt a rate of 6U ml/min.
B~ revezee-phase HPLC quantiution, after reductive work-up with NaBH4.
3 Ensmine VIII itenerated at -4D° C (Procedure K (ii)).
1341'262 Table 5. Effect of Time of Oxidation on Production of Vinblastine (I) froa Enamine VIII3 Timel (min) a Yield of 2 Vinblastine 1 8.2 15.4 15.5 15.7 45 6.5 Reaction conditions: - 2 eq. ferric chlorine added, air bubbled throu,~ the solution at 60 ~1/min at 0° C.
2 By reverse-phase BpI~C quaatitation aftxr reductive work-up s~ith NaBIi4.
~namine DIII generated at -40° C (Procedure K (ii)).
13412fi2 ~abie E. Effect of Oxidation TemperaturE on Production of t~inbiastine (I) f roa Ena~ine VIII3 TemF., ° CI ~ Yield of 2 vinblastine -40 3..
-23 6.?
0 19.6 20 20.6 16.0 Reaction conditions: 2 eq. ferric chloride added, air bubbled through the solution at 60 sl/~in for 15 mir..
By reverse-phase HPLC quantitation after reductive work-up with NaBP.4.
Enamine generated at -40° C (Procedure K (fi)).
Table 7. Effect of Dilution on Production of Vinblastine (I) frog Enamine vIIT3 Dilution Factorl'4 1 Yield of 2 Vinblastine 1 19.6 25.2 30.1 29.6 50 24.7 1 iteactian conditions: 2 eq. ferric chloride added, air bubbled through the solution at 60 slain for 15 :in. at 0° C.
2 By reverse-phase xPI~C quantitation after reductive work-up with NaBIi4.
Enamine Generated at -40° C (Procedure R (ii)).
~' Dilution Factor 1 ~ 100 ~g Isinium 'VI in 6 :1 sethanol to ~rhich reducing agent Formula III (6 aq.) in 6 st2 ~ethaaol vas added.
(Total voluae ~ 1~ ~1) Dilution Factor 5 ~ Total voltme of b0 ml, etc.
13412fi2 Table 5 indicates results relating to yield of vinblastine versus time of oxidation. The maximum yield of vinblastine (I) is reached after 5 to 20 minutes of aeration in the presence of 2 equivalents of ferric chloride.
Table 6 shows the results of various oxidation temperatures, in the presence of two equivalents of ferric chloride, on the yield of vinblastine (I). The temperature range of 0°C to 20°C provides the highest yield of vinblastine (I) after a reductive work-up with NaBH4, as quantified by reverse-phase HPLC.
The effect of dilution of the enamine (VIII) solution on the production of vinblastine (I), is indicated in Table 7. A dilution factor of 10 to 20 on the enamine (VIII) solution before aeration in the presence of ferric chloride (2 equivalents) at 0°C, affords the best yield of vinblastine (I) as quantified by reverse-phase HPLC after reductive work-up with NaBH4.
In summary, the specific improvements in the present application as they relate to the oxidative trans-formation of the enamine (VIII), involve the dilution (5 to 50 folds) of the enamine (Formula VIII) solution, obtained in the above reduction of iminium intermediate (Formula VI), by the same solvent used in the reduction. For practical purposes, the preferred dilution factor is usually in the range of 8 to 12 folds. The above procedure is conducted at a low temperature (0°C to -70°C), preferably below -40°C and under cover with inert conditions such as argon or an inert gas of Group Zero of the Periodic Table (nitrogen, helium, neon, etc.). After this dilution process, the oxidative transformation of the enamine (Formula VIII) can be carried out as described above (aeration at 60 ml/min for 15 min at 0°C in the presence of ferric chloride (2 eq.)) to afford the corresponding iminium intermediates (Formula XVI).
OOf l N...
- _H_ -~.- t7-r H ,.:
_~ I
vindof ine O OH
CH30 ~ ~O~ "CH3 Formula RVI
The third area of improvement relates to the reduction of iminium intermediates (Formula XVI) by alkali metal borohydride (NaBH4, KBH4, LibH4, etc.) to vinblastine (Formula I) and/or leurosidine (Formula XXXV). The iminium intermediates (Formula XVI and Formula XVIa) produced from the oxidative transformation of enamine (Formula VIII) are reduced by the addition of alkali metal borohydride at low temperature (4°C to -20°C), preferably at 0°C. The reduc-tion is conducted at pH lower than 8.5 and preferably at 7.5 to 8. The total reaction mixture is then concentrated in vacuo at low temperature (0°C to 10°C) before extraction and isolation of alkaloid products.
1 347 2fi 2 H
I R N ~ ~ ~t oo~
O RN-H'w~--~ I 1 _H_.-w ~"'~
I
off CH30 N~O~ -CH3 O OH
CH3 R 0 CH3 0 ~~ Oy'CH3 R=COy~i3 CH3~ 0 R=C0yCH3 Formula XXXV (Leurosidine) Formula XVIa For practical purposes, all the above improvements can be incorporated, as indicated, directly into the overall process conducted in a one-pot operation from the indole unit (Formulas II, XXII or XXIII) and the dihydroindole unit (Formula XXI, R - H) to the final products of Formula XXI.
Isolation of the various intermediates (Formulas XXIV, VI, VIII and XVI) is omitted as summarized in Scheme 1.
In summary, the present method is applicable to the production of dimer products from catharanthine and dihydrocatharanthine with vindoline as starting materials and phenyl, alkyl and amide derivatives embraced by the following formulas:
Scneme 1. Optimum procedure for one-pot process - vinblastine from catharanthine and vindoline.
D
r ca~c~
XXtV
~C~3CO~Z O l 1 _60 o C !i 0 t OH ~ _Cti~
C, yr OKs o (r CONIiZ
l t 3 c t.Z-Reduction f Enamine Anhydrovinbls~tme R~tso t.Z:1 1 34i 262 Scneu~_ : - cor,:inue~
h' ..
J
CH~O ~''~''~'!~~-Ct~
R ~ Gp2Ct~3 vllt FeCI 2 a uiv.), 0° C
Air. ~~ mi9min. !5 min Dilution Factor 10 00 ff ~ ooH
CiisO ~~ ~~~_C~~
XVI
XVIe NvBii~ N~Bfix _C+~i X341262_ Formula XXI is as pictured and in that formula alk represents a lower alkyl group of Cl-C6 and preferably Cl-C3; aryl is mono-aryl such as benyzl, styryl, and xylyl; Rl is a member of the group consisting of hydrogen, alk, CHO
and COR5 where R5 is alkyl or aryl; R2 and R3 are members of the group consisting of hydrogen and -CO-alk; R4 is a member of the group consisting of COO-alk, CONH-NH2, CONH2, CONHR6, and CON(R6)2 where R6 is alkyl; Z is a member of the group consisting of -CH2-CH2- and -CH-CH- and R is a member of the indole family represented by Formula XXII
where R~ is a member of the group consisting of hydrogen, or COO-alk; R8 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk or alkyl; R9 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk, or alk; R10 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk, or Formula XXIII where R11 is a member of the group consisting of hydrogen or COO-alk; R12 is a member consisting of alkyl.
SEecific Description of the Invention This invention is specifically a process for the production of compounds represented by the following formulas:
s XXI
n s' o-~z iO n ~ i 1W' 13412fi2 xIi x XXIII
G
wherein in Formula XXI
Alkyl = CH3 or (CH2)nXH3 where n=1-5 Rl - CH3 or CHO
R2 - H or CO-alk R4 - COO-alk or CONR13R14 where R13 and R14 can be any member of the group consisting of hydrogen, alkyl, substituted alkyl, aryl or substituted aryl functions Z - -CH=CH- or -CH2-CH2-R - Formula XXII or XXIII
R~ - or COO-alk H
R8 - OH, O-alk, OCO-alk or alkyl H, R~ - OH, O-alk, OCO-alk or alkyl H, R1~ - OH, O-alk, OCO-alk H, R11 - or COO-alk H
R12 - or alkyl H
wherein the process a dimer derived is for the synthesis of from an indole unit of the natural Iboga alkaloid family containing an a dihydroindole aza bicyclo-octane portion and 13~~~62 unit of the natural Aspidosperma and Vinca alkaloid families, the stereochemistry of the carbon-carbon linkage between these two units being identical with that of vinblastine which consists of (a) forming an N-oxide intermediate in the cold at a temperature of -70°C to +40°C from said indole unit by oxidizing the bridge nitrogen and without isolating said intermediate;
(b) treating said 2~-oxide indole intermediate in the presence of one member of the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride to effect a Polonovski-type fragmentation reaction;
(c) without isolating the product of step (b), coupling said reaction product with a dihydroindole unit in the presence of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to +40°C under inert conditions;
(d) the product of step (c) is solated by solvent evaporation preferably at low temperature in the range of -20°C to 0°C;
(e) the product of step (d) is reduced by 1,4-dihydropyridine compounds represented by Formula IX
H Rw R R, IX
~Z
Ri where R3 and R5 in Formula IX are carboxylic esters (COO-alk) and Rl, R2, R4 and R6 are members of the group consisting of H, alkyl, aryl (Hantzch ester series) or tv-substituted 1,4-dihydronicotinamides where R1 is a substituted alkyl or substituted aryl function, for example, benzyl, and R3 is CONR~RB where R~ and R8 is one member of the group consisting of hydrogen, alkyl or aryl function;
(f) the product of step (e), an enamine, Formula VIII, is isolated by solvent evaporation, preferably at low temperature in the range of -20°C to 0°C;
(g) the product of step (e), a solution of enamine VIII, is diluted (5 to 50 folds) by the same solvent employed, preferably in the range of 8 to 12 folds at a low temperature (0°C to -70°C), preferably below -40°C;
(h) the enamine obtained in step (f) or the enamine solution obtained in step (g) is used to prepare iminium intermediates, Formula XVI or XVIa, by a number of oxidative processes including:
(1) controlled aeration/oxygenation in which a solution of the enamine is stirred in open air or with a stream of air/oxygen bubbled through the solution;
(2) as in (1) but with the addition of a metal ion;
(3) as in (1) but with the addition of a flavin coenzyme, as represented by Formula XII, to generate, in situ, the corresponding 1,5-dihydroflavin coenzyme, as represented by Formula XIII;
(4) as in (1) but with the addition of hydrogen peroxide and/or hydroperoxides as represented by the Formula R-OOH where R is alkyl or aryl (i) the product, an iminium intermediate or iminium intermediates obtained in step (h) is isolated by sovlent evaporation, preferably at low temperature in the range of -20°C to 0°C;
(j) the product obtained in step (i) or the iminium intermediate solution obtained in step (h) is converted to the target compounds of Formula XXI, for which vinblastine and vincristine are examples and leurosidine (Formula XXXV) by reduction with alkali metal borohydride (NaBH4, KBH4, LiBH4) in suitable solvents (organic and/or aqueous) as used in the oxidative processes of step (h).
Of special importance is the presence of electron rich functional groups (e.g., caqrboxylic esters and carboxylate salts) in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Some examples of these 1,4-dihydropyridine compounds are given in Table 1 (e. g., Formulas XXXI and XXXII). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII).
The reduction is conducted under an inert atmosphere at -60°C to +60°C but preferably in the temperature range -20°C to -40°C. The solvents employed are alcohols, acetonitrile or higher members of this series, dimetheyl sulfoxide, dimethylformamide, various ethers such as dioxane and tetrahydrofuran, and chlorinated hydrocarbons.
The oxidative processes in step (h) (1)-(4) are conducted in organic solvents such as alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylformamide, various ethers such as dioxane, tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, etc. An aqueous buffer (e. g., phosphate, Tris-HC1, MES buffers) at pH 5-9, but preferably in the range of 6-8, can be used as co-solvent. The reaction temperature may vary from -60°C to +60°C.
Of special importance is the presence of electron rich functional groups (e.g., caqrboxylic esters and carboxylate salts) in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Some examples of these 1,4-dihydropyridine compounds are given in Table 1 (e. g., Formulas XXXI and XXXII). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII).
The reduction is conducted under an inert atmosphere at -60°C to +60°C, but preferably in the temperture range of -20°C to -40°C. The solvents employed are alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylformamide, various ethers such as dioxane and tetrahydrofuran and chlorinated hydrocarbons.
The product of step (e) above, an enamine, Formula VIII, is isolated by solvent evaporation, preferably at low temperature in the range of -20°C to 0°C.
The process of this invention also prepares an ~3~~2sz enamine and oxidizes said enamine to the iminium inter-mediate (Formula XVI and XVIa) by a number of oxidative processes including:
(a) controlled aeration/oxygenation in which a solution of the enamine is stirred in open air with a stream of air/oxygen bubbled through the solution;
(b) as in step (h)(1) but with the addition of a ferric chloride;
( c ) as in step ( h ) ( 1 ) but with the addition of a flavin coenzyme, as represented by Formula XII:
..OH
1~ ~1~~0 XII
w to generate, in situ, the corresponding 1,5-dihydroflavin coenzyme, as represented by Formula XIII
XIII
H
i NN
f1 The oxidative processes are conducted in organic solvents such as alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylforman;ide, ethers such as dioxane, tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, etc.
EXAMPLES
The following examples (Examples 1 - 8) were conducted at 20°C.
Example 1 Reduction of Iminium Intermediate (Formula VI) with 1-Diphenylmethyl (-1,4-dihydronicotinamide (Formula IX, R1 -Biphenyl methyl; R2 = R4 = R5 = R6 = H; R3 = CONH2) (Formula XXVII) - Synthesis of Enamine (Formula VIII) - Procedure C) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed ethanol (6 ml) was added 1-diphenylmethyl-1,4-dihydronicotinamide (Formula XXVII) (76 mg, 2.5 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse phase HPLC analysis (Waters Radial-Pak C18 or CtJ cartridge, methanol-H20-Et3N as solvent system) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 0.9:1 (60$
yield).
Example 2 Reduction of Iminium Intermediate (Formula VI) with 1-Benzyl-3-cyano-1,4-dihydropyridine (Formula IX, Rl - benzyl;
R2 = R4 = R5 = R6 = H; R3 = CN) (Formula XXXIII) - Synthesis of Enamine (Formula VIII) - (Procedure D).
To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1-benzyl-3-cyano-1,4-dihydropyridine (Formula XXXIII) (206 mg, 10 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1:1 (40~ yield).
Example 3 Reduction of Iminium Intermediate (Formula VI) with 1-Benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide (Formula IX, Rl = benzyl; R2 - R4 - R5 - R6 - H; R3 -(2' carbamoyl-pyrrolidinyl) carbonyl) (Formula XXXIV) -Synthesis of Enamine VIII) - (Procedure E).
To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1-benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide (Formula XXXIV) (163 mg, 5 equivalents) in methanol (5 ml) under a positive pressure of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 3U min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.1:1 (60~
yield).
Example 4 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(1-methoxycarbonyl isobutyl)-nicotinamide (Formula IX, R1 - 1-methoxycarbonyl isobutyl; R~ - R4 - R5 - R6 - H;
R3 - CONH2) (Formula XXVIII) - Synthesis of Enamine (Formula VIII) - (Procedure F) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(1-methoxy carbonylisobutyl)-nicotinamide (Formula XXVIII) (150 mg, 6 equivalents) in methanol (6 ml) under a positive pressure of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 2:1 (65~
yield).
Example 5 Reduction of Iminium Intermediate (Formula VI) with 1-(2',3',4',6'-Tetraacetyl-(beta)-D-glucopyranosidyl)-1,4-dihydronicotinamide (Formula IX, R1 - (2',3',4',6'-Tetra-acetyl-(beta)-D-glucopyranosidyl; R2 - R4 - R5 - R6 - H; R3 - CONH2) (Formula XXIX) - Synthesis of Enamine (Formula VIII) - (Procedure G) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) ws added 1-(2',3',4',6'-tetra-acetyl-(beta)-D-glycopyranosidyl)-1,4-dihydronicotin-amide (Formula XXIX) (238 mg, 5 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.5:1 (70~ yield).
Example 6 Reduction of Iminium Intermediate (Formula VI) with 1,4-Di-hydro-1-(2'-methoxycarbonyl isopropyl)-nicotinamide (Formula IX, Rl - 2' -methox;~ carbonylisopropyl; R2 - R4 - R5 - R6 -H; R3 = CONH2) (Formula XXX) - Synthesis of Enamine (Formula VIII) - (Procedure H) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(2'-methoxy-carbonylisopropyl)-nicotinamide (Formula XXX) (82 mg, 3.5 equivalents) in methanol (7 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of l.l:l (65~
yield).
Example 7 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(1',2'-dimethoxy carbonyl ethyl 1, R2 - R4 - R5 -R6 - H; R3 - CONH2) (Formula XXXI) - Synthesis of Enamine (Formula VIII) - Procedure I) To a solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(1',2'-dimethoxy carbonyl ethyl)-nicotinamide (Formula XXXI) (148 mg, 5 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added i 341 2s 2 portionwise at the rate cf 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.1:1 (70~
yield).
Example 8 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula IV, Rl - sodium-isobutyl-1-carboxylate; R2 - R4 -R5 - R6 - H; R3 - CONH2) (Formula XXXII) - Synthesis of Enamine (Formula VIII) - (Procedure J) To a solution of iminium intermediaqte (VI, 100 mg) in degassed methanol (6 ml) wqs added 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (130 mg, 5 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 2.2:1 (70~
yield).
Example 9 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula IX, R1 - sodium-isobutyl-1-carboxylate; R2 - R4 -R5 - R6 - H; R3 - CONH2) (Formula XXXII) at low temperature - Synthesis of Enamine (Formula VIII) (Procedure K) (i) To a solution of iminium intermediate (VI, 100 13~12fit mg) in degassed methanol (6 ml) at -20°C was added 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (155 mg, 6 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added in one portion. After 45 min. at this temperature reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 3.2:1 (80$ yield).
(ii) Carrying out the reaction above at -40°C
gave, after 60 minutes, enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 4.2:1 (85$ yield).
Example 10 Synthesis of Vinblastine (Formula I) by Oxidation of Enamine (Formula VIII) to Iminium Intermediate (Formula XVI) with Air in the Presence of Ferric Chloride at High Dilution.
(Method 5) The solution containing the enamine (VIII), (Procedure K (ii)) obtained from the iminium intermediate (VI, 200 mg) was diluted five-fold with methanol before oxidation (total vol.: 120 ml). Ferric chloride (75 mg, 2 equivalents) was then added, and air bubbled through the solution, at 0°C, for 20 min. Sodium borohydride (200 mg) was added, and the solution concentration in vacuo before adding water (100 ml) and extracting with ethyl acetate (3 x 200 ml). The combined organic extract was dried over Na2S04 and the solvent evaporated in vacuo. The crude product was purified by column chromatography (silica gel, TLC grade, 15 g). Elution with ether: chloroform (10:7) gave 3',4'-de-hydrovinblastine (VII, 18 mg, 11~). Further elution with ether: chloroform: methanol (10:7:0.5) gave vinblastine (I, 62 mg, 37$).
Example 11 One-Pot Conversion of Catharanthine (Formula II) and Vindoline (Formula III) to Vinblastine (Formula I) and Leurosidine (Formula XXXV) - Overall Procedure To a solution of catharanthine (II, 500 mg, 1.5 mmol) in dry dichloromethane (4.5 ml) at -15°C under a positive atmosphere of argon was added m-chloroperbenzoic acid (330 mg, 1.9 mmol) in one portion, and the mixture stirred at -10 to -15°C for 5 minutes. After this time the reaction mixture was cooled to -40°C and a solution of vindoline (III, 450 mg, 1 mmol) in dry dichloromethane (1 ml) was added, followed immediately by trifluoroacetic anhydride (1 ml, 7.1 mmol). After 2 h at -60°C volatiles were removed in vacuo (high vacuum pump) and dry, degassed methanol (12 ml) added after flushing the system with argon.
The resulting orange solution was cooled to -40°C and a solution of 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (1.5 g, 6 mmol) in dry degassed methanol (12 ml) was added under a positive atmosphere of argon. After reduction was complete (by reverse-phase HPLC
monitoring), cold methanol (about 300 ml) was added, keeping the temperature of the solutionn between -5 and 0°C. Ferric chloride (330 mg, 2 mmol) was then added and dry air bubbled through the solution at a rate of 60 ml/min for a period of 20 min. Sodium borohydride (1 g) was added and the solution 1 3~~ 2s 2 concentrated in vacuo (water aspirator) before adding water (100 ml) and extracting with ethyl acetate (3 X 150 ml).
The combined organic extract was dried over Na2S04 and the solvent evaporated in vacuo to give the crude product which was purified by chromatography as previously described to give 3',4'-dehydrovinblastine (VIII, 95 mg, 12~), vin-blastine (I, 315 mg, 39~) and leurosidine (XXXV, 130 mg, 16$).
(j) the product obtained in step (i) or the iminium intermediate solution obtained in step (h) is converted to the target compounds of Formula XXI, for which vinblastine and vincristine are examples and leurosidine (Formula XXXV) by reduction with alkali metal borohydride (NaBH4, KBH4, LiBH4) in suitable solvents (organic and/or aqueous) as used in the oxidative processes of step (h).
Of special importance is the presence of electron rich functional groups (e.g., caqrboxylic esters and carboxylate salts) in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Some examples of these 1,4-dihydropyridine compounds are given in Table 1 (e. g., Formulas XXXI and XXXII). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII).
The reduction is conducted under an inert atmosphere at -60°C to +60°C but preferably in the temperature range -20°C to -40°C. The solvents employed are alcohols, acetonitrile or higher members of this series, dimetheyl sulfoxide, dimethylformamide, various ethers such as dioxane and tetrahydrofuran, and chlorinated hydrocarbons.
The oxidative processes in step (h) (1)-(4) are conducted in organic solvents such as alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylformamide, various ethers such as dioxane, tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, etc. An aqueous buffer (e. g., phosphate, Tris-HC1, MES buffers) at pH 5-9, but preferably in the range of 6-8, can be used as co-solvent. The reaction temperature may vary from -60°C to +60°C.
Of special importance is the presence of electron rich functional groups (e.g., caqrboxylic esters and carboxylate salts) in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Some examples of these 1,4-dihydropyridine compounds are given in Table 1 (e. g., Formulas XXXI and XXXII). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII).
The reduction is conducted under an inert atmosphere at -60°C to +60°C, but preferably in the temperture range of -20°C to -40°C. The solvents employed are alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylformamide, various ethers such as dioxane and tetrahydrofuran and chlorinated hydrocarbons.
The product of step (e) above, an enamine, Formula VIII, is isolated by solvent evaporation, preferably at low temperature in the range of -20°C to 0°C.
The process of this invention also prepares an ~3~~2sz enamine and oxidizes said enamine to the iminium inter-mediate (Formula XVI and XVIa) by a number of oxidative processes including:
(a) controlled aeration/oxygenation in which a solution of the enamine is stirred in open air with a stream of air/oxygen bubbled through the solution;
(b) as in step (h)(1) but with the addition of a ferric chloride;
( c ) as in step ( h ) ( 1 ) but with the addition of a flavin coenzyme, as represented by Formula XII:
..OH
1~ ~1~~0 XII
w to generate, in situ, the corresponding 1,5-dihydroflavin coenzyme, as represented by Formula XIII
XIII
H
i NN
f1 The oxidative processes are conducted in organic solvents such as alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylforman;ide, ethers such as dioxane, tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, etc.
EXAMPLES
The following examples (Examples 1 - 8) were conducted at 20°C.
Example 1 Reduction of Iminium Intermediate (Formula VI) with 1-Diphenylmethyl (-1,4-dihydronicotinamide (Formula IX, R1 -Biphenyl methyl; R2 = R4 = R5 = R6 = H; R3 = CONH2) (Formula XXVII) - Synthesis of Enamine (Formula VIII) - Procedure C) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed ethanol (6 ml) was added 1-diphenylmethyl-1,4-dihydronicotinamide (Formula XXVII) (76 mg, 2.5 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse phase HPLC analysis (Waters Radial-Pak C18 or CtJ cartridge, methanol-H20-Et3N as solvent system) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 0.9:1 (60$
yield).
Example 2 Reduction of Iminium Intermediate (Formula VI) with 1-Benzyl-3-cyano-1,4-dihydropyridine (Formula IX, Rl - benzyl;
R2 = R4 = R5 = R6 = H; R3 = CN) (Formula XXXIII) - Synthesis of Enamine (Formula VIII) - (Procedure D).
To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1-benzyl-3-cyano-1,4-dihydropyridine (Formula XXXIII) (206 mg, 10 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1:1 (40~ yield).
Example 3 Reduction of Iminium Intermediate (Formula VI) with 1-Benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide (Formula IX, Rl = benzyl; R2 - R4 - R5 - R6 - H; R3 -(2' carbamoyl-pyrrolidinyl) carbonyl) (Formula XXXIV) -Synthesis of Enamine VIII) - (Procedure E).
To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1-benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide (Formula XXXIV) (163 mg, 5 equivalents) in methanol (5 ml) under a positive pressure of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 3U min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.1:1 (60~
yield).
Example 4 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(1-methoxycarbonyl isobutyl)-nicotinamide (Formula IX, R1 - 1-methoxycarbonyl isobutyl; R~ - R4 - R5 - R6 - H;
R3 - CONH2) (Formula XXVIII) - Synthesis of Enamine (Formula VIII) - (Procedure F) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(1-methoxy carbonylisobutyl)-nicotinamide (Formula XXVIII) (150 mg, 6 equivalents) in methanol (6 ml) under a positive pressure of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 2:1 (65~
yield).
Example 5 Reduction of Iminium Intermediate (Formula VI) with 1-(2',3',4',6'-Tetraacetyl-(beta)-D-glucopyranosidyl)-1,4-dihydronicotinamide (Formula IX, R1 - (2',3',4',6'-Tetra-acetyl-(beta)-D-glucopyranosidyl; R2 - R4 - R5 - R6 - H; R3 - CONH2) (Formula XXIX) - Synthesis of Enamine (Formula VIII) - (Procedure G) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) ws added 1-(2',3',4',6'-tetra-acetyl-(beta)-D-glycopyranosidyl)-1,4-dihydronicotin-amide (Formula XXIX) (238 mg, 5 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.5:1 (70~ yield).
Example 6 Reduction of Iminium Intermediate (Formula VI) with 1,4-Di-hydro-1-(2'-methoxycarbonyl isopropyl)-nicotinamide (Formula IX, Rl - 2' -methox;~ carbonylisopropyl; R2 - R4 - R5 - R6 -H; R3 = CONH2) (Formula XXX) - Synthesis of Enamine (Formula VIII) - (Procedure H) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(2'-methoxy-carbonylisopropyl)-nicotinamide (Formula XXX) (82 mg, 3.5 equivalents) in methanol (7 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of l.l:l (65~
yield).
Example 7 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(1',2'-dimethoxy carbonyl ethyl 1, R2 - R4 - R5 -R6 - H; R3 - CONH2) (Formula XXXI) - Synthesis of Enamine (Formula VIII) - Procedure I) To a solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(1',2'-dimethoxy carbonyl ethyl)-nicotinamide (Formula XXXI) (148 mg, 5 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added i 341 2s 2 portionwise at the rate cf 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.1:1 (70~
yield).
Example 8 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula IV, Rl - sodium-isobutyl-1-carboxylate; R2 - R4 -R5 - R6 - H; R3 - CONH2) (Formula XXXII) - Synthesis of Enamine (Formula VIII) - (Procedure J) To a solution of iminium intermediaqte (VI, 100 mg) in degassed methanol (6 ml) wqs added 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (130 mg, 5 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 2.2:1 (70~
yield).
Example 9 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula IX, R1 - sodium-isobutyl-1-carboxylate; R2 - R4 -R5 - R6 - H; R3 - CONH2) (Formula XXXII) at low temperature - Synthesis of Enamine (Formula VIII) (Procedure K) (i) To a solution of iminium intermediate (VI, 100 13~12fit mg) in degassed methanol (6 ml) at -20°C was added 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (155 mg, 6 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added in one portion. After 45 min. at this temperature reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 3.2:1 (80$ yield).
(ii) Carrying out the reaction above at -40°C
gave, after 60 minutes, enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 4.2:1 (85$ yield).
Example 10 Synthesis of Vinblastine (Formula I) by Oxidation of Enamine (Formula VIII) to Iminium Intermediate (Formula XVI) with Air in the Presence of Ferric Chloride at High Dilution.
(Method 5) The solution containing the enamine (VIII), (Procedure K (ii)) obtained from the iminium intermediate (VI, 200 mg) was diluted five-fold with methanol before oxidation (total vol.: 120 ml). Ferric chloride (75 mg, 2 equivalents) was then added, and air bubbled through the solution, at 0°C, for 20 min. Sodium borohydride (200 mg) was added, and the solution concentration in vacuo before adding water (100 ml) and extracting with ethyl acetate (3 x 200 ml). The combined organic extract was dried over Na2S04 and the solvent evaporated in vacuo. The crude product was purified by column chromatography (silica gel, TLC grade, 15 g). Elution with ether: chloroform (10:7) gave 3',4'-de-hydrovinblastine (VII, 18 mg, 11~). Further elution with ether: chloroform: methanol (10:7:0.5) gave vinblastine (I, 62 mg, 37$).
Example 11 One-Pot Conversion of Catharanthine (Formula II) and Vindoline (Formula III) to Vinblastine (Formula I) and Leurosidine (Formula XXXV) - Overall Procedure To a solution of catharanthine (II, 500 mg, 1.5 mmol) in dry dichloromethane (4.5 ml) at -15°C under a positive atmosphere of argon was added m-chloroperbenzoic acid (330 mg, 1.9 mmol) in one portion, and the mixture stirred at -10 to -15°C for 5 minutes. After this time the reaction mixture was cooled to -40°C and a solution of vindoline (III, 450 mg, 1 mmol) in dry dichloromethane (1 ml) was added, followed immediately by trifluoroacetic anhydride (1 ml, 7.1 mmol). After 2 h at -60°C volatiles were removed in vacuo (high vacuum pump) and dry, degassed methanol (12 ml) added after flushing the system with argon.
The resulting orange solution was cooled to -40°C and a solution of 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (1.5 g, 6 mmol) in dry degassed methanol (12 ml) was added under a positive atmosphere of argon. After reduction was complete (by reverse-phase HPLC
monitoring), cold methanol (about 300 ml) was added, keeping the temperature of the solutionn between -5 and 0°C. Ferric chloride (330 mg, 2 mmol) was then added and dry air bubbled through the solution at a rate of 60 ml/min for a period of 20 min. Sodium borohydride (1 g) was added and the solution 1 3~~ 2s 2 concentrated in vacuo (water aspirator) before adding water (100 ml) and extracting with ethyl acetate (3 X 150 ml).
The combined organic extract was dried over Na2S04 and the solvent evaporated in vacuo to give the crude product which was purified by chromatography as previously described to give 3',4'-dehydrovinblastine (VIII, 95 mg, 12~), vin-blastine (I, 315 mg, 39~) and leurosidine (XXXV, 130 mg, 16$).
Claims (16)
1. A process for the production of dimer alkaloid compounds comprising the steps of:
(a) oxidizing an indole unit having a bridge nitrogen and being represented by the following formula:
wherein R represents hydrogen or COO-alkyl, said oxidation being carried out in the cold, at a temperature from about -77 °C to about +40 °C, thereby oxidizing the bridge nitrogen of said indole unit and forming an N-oxide derivative as represented by the following formula:
wherein R is the same as above, and without isolating said derivative;
(b) treating said N-oxide derivative in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride, to effect a Polonovski-type fragmentation reaction;
(c) without isolating the product of step (b), stereospecifically coupling said product of step (b) with a dihydroindole unit represented by the formula:
said coupling being conducted in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to about +40°C, under inert conditions, to form a first iminium intermediate, represented by the formula:
(d) reducing said first iminium intermediate by reaction with a 1,4-dihydropyridine compound, represented by the formula:
wherein R1 is H, alkyl, substituted alkyl, aryl, substituted aryl and sugar units;
R2, R4 and R6, independently, are H, alkyl or aryl;
R3 is cyano, CONR7R8 wherein R7 and R8 independently may be H, alkyl, aryl, or taken together, R7 and R8 can form a ring structure containing up to four carbon atoms, said ring structure may further be substituted by CONR9R10, wherein R9 and R10 are H or alkyl; and R5 may be H, alkyl, carboxylate and salts thereof, and aryl;
with the proviso that, when R3 is CONH2, and R2, R4, R5 and R6 are H, then R1 is other than benzyl;
thereby forming an enamine intermediate, represented by the following formula:
(e) transforming said enamine intermediates obtained in step (d) by oxidation under controlled aeration conditions in the presence of ferric chloride to a second iminium intermediate, as represented by the following formula:
wherein:
R x is OOH or C2H5 and R y is OOH or C2H5, with the proviso that R x and R y cannot be the same; and (f) reducing the second iminium intermediate obtained in step (e) to form said dimer alkaloid compounds, represented by the formula:
wherein: R x and R y are OH or C2H5, with the proviso that R x and R y cannot be the same.
(a) oxidizing an indole unit having a bridge nitrogen and being represented by the following formula:
wherein R represents hydrogen or COO-alkyl, said oxidation being carried out in the cold, at a temperature from about -77 °C to about +40 °C, thereby oxidizing the bridge nitrogen of said indole unit and forming an N-oxide derivative as represented by the following formula:
wherein R is the same as above, and without isolating said derivative;
(b) treating said N-oxide derivative in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride, to effect a Polonovski-type fragmentation reaction;
(c) without isolating the product of step (b), stereospecifically coupling said product of step (b) with a dihydroindole unit represented by the formula:
said coupling being conducted in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to about +40°C, under inert conditions, to form a first iminium intermediate, represented by the formula:
(d) reducing said first iminium intermediate by reaction with a 1,4-dihydropyridine compound, represented by the formula:
wherein R1 is H, alkyl, substituted alkyl, aryl, substituted aryl and sugar units;
R2, R4 and R6, independently, are H, alkyl or aryl;
R3 is cyano, CONR7R8 wherein R7 and R8 independently may be H, alkyl, aryl, or taken together, R7 and R8 can form a ring structure containing up to four carbon atoms, said ring structure may further be substituted by CONR9R10, wherein R9 and R10 are H or alkyl; and R5 may be H, alkyl, carboxylate and salts thereof, and aryl;
with the proviso that, when R3 is CONH2, and R2, R4, R5 and R6 are H, then R1 is other than benzyl;
thereby forming an enamine intermediate, represented by the following formula:
(e) transforming said enamine intermediates obtained in step (d) by oxidation under controlled aeration conditions in the presence of ferric chloride to a second iminium intermediate, as represented by the following formula:
wherein:
R x is OOH or C2H5 and R y is OOH or C2H5, with the proviso that R x and R y cannot be the same; and (f) reducing the second iminium intermediate obtained in step (e) to form said dimer alkaloid compounds, represented by the formula:
wherein: R x and R y are OH or C2H5, with the proviso that R x and R y cannot be the same.
2. The process according to claim 1, wherein R1 is arylalkyl, diarylalkyl, alkoxycarbonylalkyl, dialkoxycarbonylalkyl, alkali metal salts thereof, and sugar units.
3. The process according to claim 1 or 2, wherein the 1,4,dihydropyridine reducing agent used in step (d) is selected from the group consisting of:
1-diphenylmethyl-(1,4-dihydronicotinamide);
1-benzyl-3-cyano-1,4-dihydropyridine;
1-benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide;
1,4-dihydro-1-(1-methyoxycarbonyl isobutyl)-nicotinamide;
1- (2', 3',4', 6'-tetraacetyl-(beta)-D-glucopyranosidyl-1,4-dihydronicotinamide;
1,4-dihydro-1-(2'-methoxycarbonyl isopropyl)-nicotinamide;
1,4-dihydro-1-(1',2'-dimethoxy carbonyl ethyl)-nicotinamide; and 1,4-dihydro-1- (sodium-isobutyl-1-carboxylate)-nicotinamide.
1-diphenylmethyl-(1,4-dihydronicotinamide);
1-benzyl-3-cyano-1,4-dihydropyridine;
1-benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide;
1,4-dihydro-1-(1-methyoxycarbonyl isobutyl)-nicotinamide;
1- (2', 3',4', 6'-tetraacetyl-(beta)-D-glucopyranosidyl-1,4-dihydronicotinamide;
1,4-dihydro-1-(2'-methoxycarbonyl isopropyl)-nicotinamide;
1,4-dihydro-1-(1',2'-dimethoxy carbonyl ethyl)-nicotinamide; and 1,4-dihydro-1- (sodium-isobutyl-1-carboxylate)-nicotinamide.
4. The process according to anyone of claims 1 to 3, further including the step of diluting said enamine obtained in step (d) by a factor of 5 to 50 fold with a solvent prior to performing step (e).
5. The process according to anyone of claims 1 to 4, wherein the oxidative transformation step (e) is conducted at a pH in the range of 6-8.
6. The process according to anyone of claims 1 to 5, wherein about two equivalents of ferric chloride are employed in step (e).
7. The process according to anyone of claims 1 to 6, wherein the time of aeration in the oxidation transformation step (e) is from about five to about twenty minutes.
8. The process according to anyone of claims 1 to 7, wherein the oxidative transformation step (e) is conducted at a temperature in the range from about 0°C to about 20°C.
9. The process according to claim 4, wherein said enamine obtained in step (d) is diluted from about 5 to about 20 fold with a solvent, prior to performing step (e).
10. The process according to claim 9, wherein said enamine is diluted 8 to 12 fold.
11. A process according to anyone of claims 1-10, wherein R is COO-alky and alkyl group is C1-C3.
12. A process according to claim 11, wherein alkyl group is CH3.
13. A process according to claim 12, wherein in the intermediate obtained in step (e), R x is OH and R y is CH2CH3 to obtain vinblastine and recovering said vinblastine.
14. A process according to claim 12, wherein in the intermediate obtained in step (e) R x is CH2CH3 and R y is OH to obtain leurosidine and recovering said leurosidine.
15. A process according to claim 12, further comprising the step of oxidizing said vinblastine to obtain vincristine, and isolating said vincristine.
16. A process for the production of 3',4'-anhydrovinblastine comprising the steps of:
(a) oxidizing catharanthine, said oxidation being carried out in the cold, at a temperature from about -77°C. to about +40°C, thereby oxidizing the bridge nitrogen of said catharanthine and forming an N-oxide derivative, and without isolating said derivative;
(b) treating said N-oxide derivative in the presence at least of one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride, to effect a Polonovske-type fragmentation reaction;
(c) without isolating the product of step (a), stereospecifically coupling said product of step (b) with vindoline said coupling being conducted in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to about +40°C, under inert conditions, to form a first iminium intermediate, represented by the formula:
(d) reducing said first iminium intermediate by reaction with a 1,4-dihydropyridine compound, represented by the formula:
wherein R1 is H, alkyl, arylalkyl, diarylalkyl, alkoxy, alkoxycarbonylalkyl, dialkoxycarbonylalkyl, alkali metal salts therof, carboxylate ester, aryl, and sugar units;
R2, R4 and R6, independently, are H, alkyl or aryl;
R3 is cyano, CONR7R8 wherein R7 and R8 independently may be H, alkyl, aryl, or taken together, R7 and R8 can form a ring structure containing up to four carbon atoms, said ring structure may further be substituted by CONR9R10, wherein R9 and R10 are H or alkyl; and R5 may be H, alkyl, carboxylate and salts thereof, and aryl;
with the proviso that, when R3 is CONH2 ,and R2, R4, R5 and R6 are H, then R1 is other than benzyl.
(a) oxidizing catharanthine, said oxidation being carried out in the cold, at a temperature from about -77°C. to about +40°C, thereby oxidizing the bridge nitrogen of said catharanthine and forming an N-oxide derivative, and without isolating said derivative;
(b) treating said N-oxide derivative in the presence at least of one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride, to effect a Polonovske-type fragmentation reaction;
(c) without isolating the product of step (a), stereospecifically coupling said product of step (b) with vindoline said coupling being conducted in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to about +40°C, under inert conditions, to form a first iminium intermediate, represented by the formula:
(d) reducing said first iminium intermediate by reaction with a 1,4-dihydropyridine compound, represented by the formula:
wherein R1 is H, alkyl, arylalkyl, diarylalkyl, alkoxy, alkoxycarbonylalkyl, dialkoxycarbonylalkyl, alkali metal salts therof, carboxylate ester, aryl, and sugar units;
R2, R4 and R6, independently, are H, alkyl or aryl;
R3 is cyano, CONR7R8 wherein R7 and R8 independently may be H, alkyl, aryl, or taken together, R7 and R8 can form a ring structure containing up to four carbon atoms, said ring structure may further be substituted by CONR9R10, wherein R9 and R10 are H or alkyl; and R5 may be H, alkyl, carboxylate and salts thereof, and aryl;
with the proviso that, when R3 is CONH2 ,and R2, R4, R5 and R6 are H, then R1 is other than benzyl.
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000543832A CA1341262C (en) | 1987-08-06 | 1987-08-06 | A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine |
| US07/228,821 US5047528A (en) | 1987-01-22 | 1988-08-02 | Process of synthesis of vinblastine and vincristine |
| DE3826412A DE3826412A1 (en) | 1987-08-06 | 1988-08-03 | METHOD FOR THE SYNTHESIS OF VINBLASTIN AND VINCRISTIN |
| SE8802813A SE467875B (en) | 1987-08-06 | 1988-08-03 | PROCEDURES FOR THE PREPARATION OF THE VINBLASTIN AND THE VINE CRYSTAL. |
| IL8734788A IL87347A (en) | 1987-08-06 | 1988-08-04 | Process for the synthesis of vinblastine and vincristine |
| NL8801966A NL8801966A (en) | 1987-08-06 | 1988-08-05 | PROCESS FOR THE PREPARATION OF VINBLASTINE AND VINCRISTINE. |
| BE8800908A BE1003228A4 (en) | 1987-08-06 | 1988-08-05 | PROCESS FOR THE SYNTHESIS OF VINBLASTINE AND VINCRISTINE |
| FR888810637A FR2622888B1 (en) | 1987-01-22 | 1988-08-05 | IMPROVED PROCESS FOR THE SYNTHESIS OF VINBLASTINE AND VINCRISTINE |
| CH2974/88A CH676711A5 (en) | 1987-08-06 | 1988-08-05 | |
| IT8821678A IT1227155B (en) | 1987-08-06 | 1988-08-05 | VINBLASTIN AND VINCRISTINE SYNTHESIS PROCEDURE. |
| AU20512/88A AU617342B2 (en) | 1987-01-22 | 1988-08-05 | Process for the synthesis of dimer alkaloid compounds |
| ZA885765A ZA885765B (en) | 1987-08-06 | 1988-08-05 | Process for the synthesis of vinblastine and vincristine |
| CN 88104941 CN1027266C (en) | 1987-08-06 | 1988-08-06 | Process for synthesis of dimer alkaloid compounds |
| JP63196999A JPH0613532B2 (en) | 1987-08-06 | 1988-08-06 | How to generate dimers |
| HU884126A HU208829B (en) | 1987-08-06 | 1988-08-08 | Process for synthetizing dimeric alkaloid compounds |
| GB8818765A GB2215331B (en) | 1987-08-06 | 1988-08-08 | Improvements in or relating to the synthesis of vinblastine and vincristine and related compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000543832A CA1341262C (en) | 1987-08-06 | 1987-08-06 | A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1341262C true CA1341262C (en) | 2001-06-26 |
Family
ID=4136214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000543832A Expired - Fee Related CA1341262C (en) | 1987-01-22 | 1987-08-06 | A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPH0613532B2 (en) |
| AU (1) | AU617342B2 (en) |
| BE (1) | BE1003228A4 (en) |
| CA (1) | CA1341262C (en) |
| CH (1) | CH676711A5 (en) |
| DE (1) | DE3826412A1 (en) |
| GB (1) | GB2215331B (en) |
| HU (1) | HU208829B (en) |
| IT (1) | IT1227155B (en) |
| NL (1) | NL8801966A (en) |
| SE (1) | SE467875B (en) |
| ZA (1) | ZA885765B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047528A (en) * | 1987-01-22 | 1991-09-10 | University Of Bristish Columbia | Process of synthesis of vinblastine and vincristine |
| USRE37449E1 (en) | 1987-02-06 | 2001-11-13 | University Of British Columbia | Process of synthesis of 3′,4′-anhydrovinblastine, vinblastine and vincristine |
| US5432279A (en) * | 1989-03-04 | 1995-07-11 | Mitsui Petrochemical Industries, Inc. | Process for the preparation of binary indole alkaloids |
| ATE182140T1 (en) * | 1990-11-30 | 1999-07-15 | Fujirebio Kk | OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| JP3010151U (en) * | 1994-04-26 | 1995-04-25 | スミ子 片山 | A cylindrical tableware storage case with a notch. |
| FR2779146B1 (en) * | 1998-06-02 | 2002-01-18 | Roowin | NOVEL VINCA-ALKALOIDE DERIVATIVES AND PREPARATION METHODS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4279817A (en) * | 1975-05-30 | 1981-07-21 | The United States Of America As Represented By The Department Of Health & Human Services | Method for producing dimer alkaloids |
| HU195513B (en) * | 1984-10-16 | 1988-05-30 | Richter Gedeon Vegyeszet | Process for producing stable solutions of alkaloides with bis-indole skeleton |
| EP0215058A1 (en) * | 1985-03-12 | 1987-03-25 | The University Of Vermont And State Agricultural College | Synthesis of vinblastine and vincristine type compounds |
| CA1341261C (en) * | 1987-01-22 | 2001-06-26 | James P. Kutney | Process for the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine |
-
1987
- 1987-08-06 CA CA000543832A patent/CA1341262C/en not_active Expired - Fee Related
-
1988
- 1988-08-03 SE SE8802813A patent/SE467875B/en not_active IP Right Cessation
- 1988-08-03 DE DE3826412A patent/DE3826412A1/en not_active Ceased
- 1988-08-05 IT IT8821678A patent/IT1227155B/en active
- 1988-08-05 BE BE8800908A patent/BE1003228A4/en not_active IP Right Cessation
- 1988-08-05 CH CH2974/88A patent/CH676711A5/de not_active IP Right Cessation
- 1988-08-05 AU AU20512/88A patent/AU617342B2/en not_active Ceased
- 1988-08-05 ZA ZA885765A patent/ZA885765B/en unknown
- 1988-08-05 NL NL8801966A patent/NL8801966A/en not_active Application Discontinuation
- 1988-08-06 JP JP63196999A patent/JPH0613532B2/en not_active Expired - Lifetime
- 1988-08-08 HU HU884126A patent/HU208829B/en not_active IP Right Cessation
- 1988-08-08 GB GB8818765A patent/GB2215331B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IT1227155B (en) | 1991-03-19 |
| JPH01151590A (en) | 1989-06-14 |
| GB8818765D0 (en) | 1988-09-07 |
| IT8821678A0 (en) | 1988-08-05 |
| AU2051288A (en) | 1989-02-09 |
| CH676711A5 (en) | 1991-02-28 |
| GB2215331B (en) | 1992-01-02 |
| HUT50351A (en) | 1990-01-29 |
| BE1003228A4 (en) | 1992-02-04 |
| JPH0613532B2 (en) | 1994-02-23 |
| SE467875B (en) | 1992-09-28 |
| SE8802813L (en) | 1989-02-07 |
| HU208829B (en) | 1994-01-28 |
| ZA885765B (en) | 1989-09-27 |
| SE8802813D0 (en) | 1988-08-03 |
| NL8801966A (en) | 1989-03-01 |
| GB2215331A (en) | 1989-09-20 |
| DE3826412A1 (en) | 1989-02-16 |
| AU617342B2 (en) | 1991-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4144237A (en) | Synthetic vinblastine and vincristine derivatives | |
| US4737586A (en) | Process for the preparation of bis-indolic compounds | |
| JP3606872B2 (en) | Antimitotic two-component alkaloid derivatives from periwinkle | |
| CA1042428A (en) | Amide derivatives of vlb and leurocristine | |
| CA1341262C (en) | A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine | |
| JPS6314783A (en) | 2-Production method of halogenated ergoline derivative | |
| Fukuda et al. | Directed C-7 lithiation of 1-(2, 2-diethylbutanoyl) indoles | |
| US5047528A (en) | Process of synthesis of vinblastine and vincristine | |
| CA1067073A (en) | Amide derivatives of vlb, leurosidine, leurocristine and related dimeric alkaloid | |
| CA1341261C (en) | Process for the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine | |
| US4191688A (en) | Amides of leurosine, leuroformine, desacetylleurosine and desacetylleuroformine | |
| US4096148A (en) | Oxazolidinedione derivatives of Vinca alkaloids | |
| Bourlot et al. | A Convenient Synthesis of 1, 2-Dihydro-3H-indol-3-ones and 1, 2-Dihydro-2H-indol-2-ones by Baeyer-Villiger Oxidation | |
| USRE37449E1 (en) | Process of synthesis of 3′,4′-anhydrovinblastine, vinblastine and vincristine | |
| Kametani et al. | Studies on the syntheses of heterocyclic compounds. 657. Total synthesis of angustine, nauclefine, and gentianine | |
| US4143041A (en) | 4'-Deoxyvincristine and related compounds | |
| US4160767A (en) | Vinca alkaloid intermediates | |
| IL87347A (en) | Process for the synthesis of vinblastine and vincristine | |
| USRE30561E (en) | Vinca alkaloid intermediates | |
| EP0001920B1 (en) | Vincaleukoblastine derivatives, a process for their preparation, pharmaceutical formulations containing them and the derivatives for use as antimitotic agents | |
| US4430269A (en) | 12'-Iodo derivatives of dimeric indole-dihydroindole alkaloids, and process for preparing them | |
| USRE30560E (en) | Oxazolidinedione derivatives of Vinca alkaloids | |
| US4159269A (en) | Preparation of oxazolidinedione derivatives of Vinca alkaloids | |
| CA1088527A (en) | 4'-deoxyvincristine and related compounds | |
| US4175080A (en) | Process of producing 5'-hydroxyleurosine and related compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |